力生製藥(002393.SZ)業績快報:2022年度淨利同比減少23.51%
格隆匯2月27日丨力生製藥(002393.SZ)披露2022年度業績快報,報吿期內,公司實現營業總收入11.47億元,同比增加5%;營業利潤1.17億元,同比減少14.54%;利潤總額1.18億元,同比減少13.89%;歸屬於上市公司股東的淨利潤9340.42萬元,同比減少23.51%;2022年,公司為提升資產運營質量,積極推進低效資產處置,完成了子公司生化製藥疫苗項目相關資產處置,產生處置損失3620.81萬元,扣除非經常性損益後的歸屬於上市公司股東的淨利潤1.25億元,同比增加7.27%。
受新冠疫情影響,公司在管理層帶領下,積極採取有力措施,在做好防疫工作的同時加緊生產,落實“保供”要求,確保市場供應。根據醫藥政策變化和市場供需情況,及時調整營銷策略和生產計劃,抓住機遇擴大產品銷售,實現營業收入同比增長。同時公司加強預算管控和能源精細化管理,有效降低運營成本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.